Genor BioPharma Appoints Dr. Qiyong Hu as Chief Financial Officer and Chief Strategy Officer

Prior to joining Genor Biopharma,Hu QiyongPh.D. inManaging Director at Deutsche BankandHead of Healthcare Industry Research, Asia-Pacific Research Division, joined Deutsche Bank in 2010 and from 2015 to 2017Consecutive Three Yearsby the internationally renowned financial magazine Institutional InvestorRanked No. 1 in China’s Best Healthcare Industry Research. As a seasoned professional in the healthcare and medical sector, Dr. Hu brings extensive experience in biotechnology, with nearly two decades of work spanning equity research, hedge funds, and multinational biopharmaceutical companies.

Dr. Hu Qiyong earned his Ph.D. from The University of Texas MD Anderson Cancer Center and began his career at Wyeth (later acquired by Pfizer). He also served asWall Street, USA'sOppenheimer Senior Biopharmaceutical Equity Analyst。

Xu Zhuo, CEO of Genor BiopharmaMr. [Name] stated, “Genor Biopharma is at a critical juncture in its global development. Dr. Hu brings extensive experience in finance and financial management within the pharmaceutical industry, and his appointment will serve as a significant addition to Genor Biopharma’s management team.”

Dr. Hu stated, “Genor Biopharma is committed to providing safe and effective treatments for patients. I look forward to joining this team to engage in the development of breakthrough innovations and cost-effective medicines, thereby creating value for all shareholders.”

Genor Biopharma is a biopharmaceutical innovation company focused on the research and development of novel therapies in oncology immunotherapy, autoimmune diseases, and other therapeutic areas. To address unmet medical needs, the company has established an integrated product pipeline spanning R&D, pharmaceutical development and industrialization, clinical studies, and commercial sales.

Among these are multiple late-stage drug candidates that are currently in or approaching pivotal trials. The company has established cGMP-compliant manufacturing facilities in Zhangjiang, Shanghai, and Yuxi, Yunnan, and has secured strategic investments from numerous renowned long-term funds.